PARIS — Kurma Partners finalized its latest investment vehicle, Biofund IV, securing €215 million in capital commitments, the venture capital firm said in a statement. Headquartered in Paris, the company designed this financial vehicle to specifically target early-stage commercial development within the specialized healthcare and therapeutics market. The successful fundraising effort received backing from prominent institutional limited partners operating across the continent with significant medical portfolios.
Those financial backers include CSL, the European Investment Fund, and Bpifrance, according to the firm. The closure of Biofund IV elevates the total assets managed by Kurma Partners to €1 billion, company records show. This massive accumulation of capital demonstrates sustained institutional confidence following the lucrative performance of their previous vehicle, Biofund III, which returned capital to investors.
That previous portfolio generated substantial returns through targeted corporate acquisitions, successfully selling startup assets to 4 multinational pharmaceutical corporations, including AstraZeneca, Eli Lilly, uniQure, and Ipsen. Fund managers at Kurma Partners plan to deploy the newly acquired capital strictly within the biopharmaceutical sector for specialized companies developing novel compounds.
The investment committee at Kurma Partners overseeing Biofund IV evaluates startups that often interact with the 4 previously mentioned pharmaceutical giants, including AstraZeneca. By focusing on highly specialized scientific research, the firm bypasses crowded consumer software markets to capture value in essential healthcare infrastructure, according to the company statement.
Securing capital from entities like CSL provides portfolio companies with immediate operational validation and extensive distribution networks, the firm said. The deployment of this €215 million fund ensures that promising laboratory discoveries backed by Kurma Partners possess the financial backing necessary to complete rigorous clinical trials.
